|
Genetic Studies of Chronic Active Epstein-Barr Disease Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Genetic Studies of Chronic Active Epstein-Barr Disease conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Genetic Studies of Chronic Active Epstein-Barr Disease Clinical research trials and Genetic Studies of Chronic Active Epstein-Barr Disease medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Genetic Studies of Chronic Active Epstein-Barr Disease. Genetic Studies of Chronic Active Epstein-Barr Disease Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Genetic Studies of Chronic Active Epstein-Barr Disease clinical trial. Participants frequently get the best healthcare available for their Genetic Studies of Chronic Active Epstein-Barr Disease condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Genetic Studies of Chronic Active Epstein-Barr Disease  Genetic Studies of Chronic Active Epstein-Barr Disease
Genetic Studies of Chronic Active Epstein-Barr Disease
For Condition: Epstein-Barr Virus Infections
Status: Recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: Epstein-Barr virus (EBV) is a member of the human herpes virus family that infects more than 95 percent of the U.S. population. Most infections occur in childhood and cause no symptoms; in adolescents and adults, EBV often causes infectious mononucleosis. It has also been associated with certain forms of cancer. Chronic Epstein-Barr virus (CAEBV) is a rare disease, primarily of children and young adults, that leads to life-threatening infections. This study seeks to identify genetic mutations responsible for CAEBV. A secondary goal is to learn more about the natural history of CAEBV. The study will examine blood and tissue samples from up to 50 patients (age 2 and above) with CAEBV and up to 150 of their relatives (age 2 and above). Autopsy samples may be included in the study. Up to 300 anonymous blood samples from the NIH Clinical Center Blood Transfusion Medicine will also be examined for comparison. No more than 450 milligrams (30 tablespoons) of blood per 8 weeks will be drawn from adult patients, and no more than 7 milliliters per kilogram of blood per 8 weeks will be drawn from patients under age 18. Local health care providers will refer patients to the study and will obtain the samples. Some patients may also be seen at the NIH Clinical Center. Those patients will have a full medical history and physical examination, along with chest X-ray, blood counts, blood chemistry, EBV serologies, and viral load. Other tests, such as CT scan or MRI, may be performed if medically indicated. Patients will be asked to undergo leukapheresis. In vitro tests on the blood or tissue samples will include analysis for proteins or genes that are involved in the immune response; cloning of portions of patient DNA; transformation of B cells with EBV; measurement of the ability of patient blood cells to kill EBV-infected cells; determination of lymphocyte subsets; and determination of antibodies to EBV or other herpes viruses. If a genetic cause for CAEBV is found, the investigators will be available to discuss the results with patients in person or by telephone. Genetic indications of risk for other diseases will also be discussed with patients.
Details: Patients with chronic active Epstein-Barr virus (CAEBV) have (a) an illness that began as a primary infection with EBV or markedly elevated titers of antibodies to EBV, (b) histological evidence of organ disease, and (c) elevated EBV DNA levels in the blood or EBV DNA or proteins in affected tissues. This is primarily a disease of children and young adults. Many of these patients develop hypogammaglobulinemia or pancytopenia and death is frequently due to opportunistic infections or B or T cell lymphoproliferative disease. The primary goal of this study is to identify genetic mutations responsible for CAEBV. The secondary goal of this study is to learn more about the natural history of CAEBV. Blood samples or available tissues (e.g. previous biopsy or autopsy material) from patients with CAEBV and their relatives will be analyzed to identify disease genes that are mutated in this population. In addition, some of the patients will be invited to come for evaluation at the NIH Clinical Center. At that time medically indicated studies of disease progression will be performed. Serial virologic and immunologic studies will be performed. Eligible relatives of patients will be studied to compare the gene(s) associated with CAEBV in patients with the gene(s) in their relatives. Knowledge gained from this study has the potential of providing insights into the immunologic control of EBV infections. In addition, identification of the molecular mechanisms for CAEBV may provide insights leading to improved treatments for this disease.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: ELIGIBILITY CRITERIA CAEBV PATIENTS Study size: up to 50 patients Sex distribution: male and female Age range: 2 years and above Patients known to have CAEBV and their relatives will be recruited by referrals from health care providers. The rarity of this disease will markedly limit the number of patients available to study. Patient recruitment is irrespective of racial and ethnic group or gender. NIAID investigators will be available to answer questions and discuss general aspects of CAEBV and identified genes or modifier genes with participants or their providers. Eligibility criteria: To be considered having CAEBV, a patient must have: (a) a severe progressive illness that began at least 6 months ago as a primary EBV infection, or associated with markedly elevated EBV-specific antibody titers (IgG-VCA greater than 1:5,120; EA greater than 1:640 or EBNA less than 1:2 with other serologies positive) not otherwise explained AND (b) evidence of major organ involvement such as lymphadenitis, hemophagocytosis, meningoencephalitis, persistent hepatitis, splenomegaly, interstitial pneumonitis, bone marrow hypoplasia, uveitis AND (c) detection of elevated levels of EBV DNA, RNA or proteins in affected tissues OR elevated levels of EBV DNA in the peripheral blood AND Exclusion criteria: (a) no other known immunocompromising condition, including HIV RELATIVES OF CAEBV PATIENTS Study size: up to 150 relatives of CAEBV patients Age range: 2 years and above To determine the genetic basis for this syndrome, the evaluation of blood and previously obtained tissue specimens from healthy relatives of CAEBV patients will serve as controls. No tissue biopsies will be performed on healthy relatives. We will perform studies on blood samples from normal relatives. UNRELATED VOLUNTEERS Study size: up to 300 persons Age range: 18 years and above Panels of anonymous blood samples will be obtained through NIH Clinical Center Blood Transfusion Medicine to determine if identified genetic changes are mutations or polymorphisms. STUDY EXCLUSIONS: Known HIV infection in any patient with CAEBV or their relative.
Total Enrollment: 200
Location and Contact Information:
National Institute of Allergy and Infectious Diseases (NIAID) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 020147; 02-I-0147
Study Start Date: March 15, 2002
Record last reviewed: March 3, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00032513
Other Epstein-Barr Virus Infections Studies:
1. Genetic Studies of Chronic Active Epstein-Barr Disease
2. Administration of EBV-Specific Cytotoxic T-Lymphocytes to Patients with EBV-Positive Cancer of the Nose and Throat
3. Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).
4. Protein Studies of the Epstein-Barr virus in Ethnically Diverse Populations
5. Treating Severe Chronic Epstein-Barr Virus (EBV) Infection with EBV Specific Cytotoxic T Lymphocytes (CTLs)
Related Studies:
Other Epstein-Barr Virus Infections Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Genetic Studies of Chronic Active Epstein-Barr Disease
|
|
|
|
|
|
|
|
